Literature DB >> 25417552

Acute escitalopram but not contextual conditioning exerts a stronger "anxiogenic" effect in rats with high baseline "anxiety" in the acoustic startle paradigm.

Robert Pettersson1, Jakob Näslund, Staffan Nilsson, Elias Eriksson, S Melker Hagsäter.   

Abstract

RATIONALE: Acute administration of selective serotonin reuptake inhibitors (SSRIs) may enhance anxiety in humans, those with anxiety disorders being more susceptible than others. Fear-conditioned or unconditioned acoustic startle and freezing are common measures of fear and/or "anxiety" in rodents that may be used to study this effect of SSRIs preclinically.
OBJECTIVES: Our aim was to shed further light on the effect of acute administration of an SSRI, escitalopram (10 mg/kg), on startle and freezing in the absence or presence of prior contextual conditioning. Repeated testing also enabled us to evaluate (i) if there are stable inter-animal variations with respect to these parameters in a batch of outbred Wistar rats, (ii) the possible relationship between the two and (iii) if baseline behaviour predicts the response to escitalopram.
RESULTS: Inter-animal test-retest correlations were found for both startle and freezing at baseline, and the two parameters also correlated with each other. Both escitalopram and contextual conditioning increased freezing and startle but without exerting any synergistic effect. While animals displaying high startle at baseline showed higher susceptibility to respond to escitalopram, the effect of conditioning was more pronounced in those with low baseline startle.
CONCLUSIONS: The results support the usefulness of both conditioned and non-conditioned startle and freezing to capture an "anxiogenic" influence of SSRIs. Also, they suggest that baseline non-conditioned startle may predict this response in a manner reflecting the clinical situation in the sense that subjects with high baseline "anxiety" are particularly prone to respond with enhanced "anxiety" following acute SSRI administration.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25417552     DOI: 10.1007/s00213-014-3783-z

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  37 in total

1.  Clomipramine and initial worsening in panic disorder: beyond the 'jitteriness syndrome'.

Authors:  R T Ramos; V Gentil; C Gorenstein
Journal:  J Psychopharmacol       Date:  1993-01       Impact factor: 4.153

2.  Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning.

Authors:  R G Phillips; J E LeDoux
Journal:  Behav Neurosci       Date:  1992-04       Impact factor: 1.912

3.  A POSSIBLE EXPLANATION OF "FREEZING" BEHAVIOR IN RATS.

Authors:  B F Riess
Journal:  Science       Date:  1945-11-30       Impact factor: 47.728

4.  Effect of co-administration of the selective 5-HT1A receptor antagonist WAY 100,635 and selective 5-HT1B/1D receptor antagonist GR 127,935 on anxiolytic effect of citalopram in conditioned fear stress in the rat.

Authors:  Ihoko Muraki; Takeshi Inoue; Tsukasa Koyama
Journal:  Eur J Pharmacol       Date:  2008-02-05       Impact factor: 4.432

Review 5.  The neuroanatomical and neurochemical basis of conditioned fear.

Authors:  M Fendt; M S Fanselow
Journal:  Neurosci Biobehav Rev       Date:  1999-05       Impact factor: 8.989

6.  Effect of citalopram, a selective serotonin reuptake inhibitor, on the acquisition of conditioned freezing.

Authors:  T Inoue; S Hashimoto; K Tsuchiya; T Izumi; T Ohmori; T Koyama
Journal:  Eur J Pharmacol       Date:  1996-09-05       Impact factor: 4.432

7.  Pharmacological dissociation of moderate and high contextual fear as assessed by freezing behavior and fear-potentiated startle.

Authors:  Julia Maria Santos; Ana Carolina Gárgaro; Amanda Ribeiro Oliveira; Sueli Masson; Marcus Lira Brandão
Journal:  Eur Neuropsychopharmacol       Date:  2005-03       Impact factor: 4.600

8.  Influence of long-term sensitization on long-term habituation of the acoustic startle response in rats: central gray lesions, preexposure, and extinction.

Authors:  G S Borszcz; J Cranney; R N Leaton
Journal:  J Exp Psychol Anim Behav Process       Date:  1989-01

Review 9.  Antidepressant-induced jitteriness/anxiety syndrome: systematic review.

Authors:  Lindsey I Sinclair; David M Christmas; Sean D Hood; John P Potokar; Andrea Robertson; Andrew Isaac; Shrikant Srivastava; David J Nutt; Simon J C Davies
Journal:  Br J Psychiatry       Date:  2009-06       Impact factor: 9.319

Review 10.  Different patterns of freezing behavior organized in the periaqueductal gray of rats: association with different types of anxiety.

Authors:  Marcus L Brandão; Janaína M Zanoveli; Raquel C Ruiz-Martinez; Luciana C Oliveira; Jesus Landeira-Fernandez
Journal:  Behav Brain Res       Date:  2007-10-25       Impact factor: 3.332

View more
  4 in total

1.  Methoxetamine affects brain processing involved in emotional response in rats.

Authors:  M T Zanda; P Fadda; S Antinori; M Di Chio; W Fratta; C Chiamulera; L Fattore
Journal:  Br J Pharmacol       Date:  2017-08-19       Impact factor: 8.739

2.  Hippocampal neural progenitor cells play a distinct role in fear memory retrieval in male and female CIE rats.

Authors:  McKenzie J Fannon; Karthik K Mysore; Jefferson Williams; Leon W Quach; Dvijen C Purohit; Britta D Sibley; Janna S Sage-Sepulveda; Khush M Kharidia; Roberto J Morales Silva; Michael J Terranova; Sucharita S Somkuwar; Miranda C Staples; Chitra D Mandyam
Journal:  Neuropharmacology       Date:  2018-09-28       Impact factor: 5.250

3.  Low startle magnitude may be a behavioral marker of vulnerability to cocaine addiction.

Authors:  Marina G Wheeler; Erica Duncan; Michael Davis
Journal:  Synapse       Date:  2016-11-18       Impact factor: 2.562

4.  A Complex Impact of Systemically Administered 5-HT2A Receptor Ligands on Conditioned Fear.

Authors:  Sven Melker Hagsäter; Robert Pettersson; Christopher Pettersson; Daniela Atanasovski; Jakob Näslund; Elias Eriksson
Journal:  Int J Neuropsychopharmacol       Date:  2021-09-21       Impact factor: 5.176

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.